Payment overview · 2025
General Payments
$616.64
32 reported records · 6 companies
Healthcare provider profile · identity verified
Abelardo J Jarava, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHICAGO, IL · NPI 1780690362
Verified facts
What the public records show
CMS Open Payments records show Abelardo J Jarava, MD received $616.64 in general payments during 2025 across 32 reported records.
Amgen Inc. accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $236.59 | 38.4% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.10 | 31.6% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.74 | 12.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.56 | 8.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.04 | 4.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.61 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.64 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $236.59 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.57 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $97.09 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $79.74 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.33 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1094 | 128 |
| Metformin Hcl | Metformin Hcl | 970 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 827 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 100 |
| Lisinopril | Lisinopril | 589 | 73 |
| Losartan Potassium | Losartan Potassium | 583 | 99 |
| Omeprazole | Omeprazole | 531 | 120 |
| Furosemide | Furosemide | 517 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 510 | 89 |
| Gabapentin | Gabapentin | 500 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 491 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 474 | 90 |
| Simvastatin | Simvastatin | 417 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 397 | 42 |
| Carvedilol | Carvedilol | 362 | 37 |
| Memantine Hcl | Memantine Hcl | 333 | 18 |
| Mirtazapine | Mirtazapine | 328 | 21 |
| Donepezil Hcl | Donepezil Hcl | 316 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 84 |
| Escitalopram Oxalate | Escitalopram Oxalate | 301 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 289 | 17 |
| Famotidine | Famotidine | 257 | 27 |
| Eliquis | Apixaban | 247 | 34 |
| Montelukast Sodium | Montelukast Sodium | 231 | 43 |
| Alprazolam | Alprazolam | 224 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 26 |
| Nifedipine Er | Nifedipine | 214 | 17 |
| Trazodone Hcl | Trazodone Hcl | 214 | 26 |
| Levetiracetam | Levetiracetam | 205 | 13 |
| Sertraline Hcl | Sertraline Hcl | 205 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 196 | 91 |
| Prednisone | Prednisone | 172 | 109 |
| Azithromycin | Azithromycin | 169 | 129 |
| Ibuprofen | Ibuprofen | 169 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 76 |
| Jardiance | Empagliflozin | 149 | 45 |
| Tramadol Hcl | Tramadol Hcl | 144 | 44 |
| Xarelto | Rivaroxaban | 135 | 11 |
| Enalapril Maleate | Enalapril Maleate | 134 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 118 | 52 |
| Potassium Chloride | Potassium Chloride | 116 | 16 |
| Risperidone | Risperidone | 114 | suppressed |
| Januvia | Sitagliptin Phosphate | 112 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 42 |
| Levofloxacin | Levofloxacin | 104 | 86 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 40 |
| Metoclopramide Hcl | Metoclopramide Hcl | 100 | 30 |
| Meloxicam | Meloxicam | 95 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | suppressed |
| Mupirocin | Mupirocin | 88 | 47 |
| Alendronate Sodium | Alendronate Sodium | 82 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 54 |
| Glipizide Er | Glipizide | 81 | 29 |
| Meclizine Hcl | Meclizine Hcl | 80 | 45 |
| Ozempic | Semaglutide | 79 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Glipizide | Glipizide | 71 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 71 | suppressed |
| Spironolactone | Spironolactone | 70 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 69 | 14 |
| Allopurinol | Allopurinol | 67 | 16 |
| Celecoxib | Celecoxib | 65 | 18 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Hydrocortisone | Hydrocortisone | 61 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 46 |
| Digoxin | Digoxin | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 56 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 11 |
| Chlorthalidone | Chlorthalidone | 52 | suppressed |
| Clonazepam | Clonazepam | 52 | 15 |
| Memantine Hcl Er | Memantine Hcl | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | 16 |
| Finasteride | Finasteride | 50 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 50 | 26 |
| Trulicity | Dulaglutide | 50 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 49 | suppressed |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 11 |
| Olanzapine | Olanzapine | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 43 | suppressed |
| Naproxen | Naproxen | 43 | 16 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 25 |
| Ondansetron Odt | Ondansetron | 39 | 25 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Etodolac | Etodolac | 36 | 25 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 17 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 12 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | 21 |
| Santyl | Collagenase Clostridium Hist. | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 18 |
| Haloperidol | Haloperidol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Valproic Acid | Valproic Acid | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Danazol | Danazol | 23 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Cefadroxil | Cefadroxil | 18 | 16 |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.64 · 32 records | Amgen Inc. | AIRSUPRA, FARXIGA, Kerendia, MOUNJARO, OTEZLA, REPATHA, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error